Kaohsiung Chang Gung Memorial Hospital - Academic Profile

Publications

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam , Johan Vansteenkiste , David Planchard +21 more

Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a compar...

2019 New England Journal of Medicine 2577 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

2019 The Lancet Oncology 1593 citations

Institution Info

Type: healthcare
Country: TW
Publications: 2
Citations: 4,170

External Links

Identifiers

ROR: https://ror.org/00k194y12